Clinical research
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.
Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
The trial found that Sci-B-Vac was non-inferior to Engerix-B, two of its primary endpoints, but it did not reach the secondary endpoint.
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.
TLC, announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicineandto bePresented During Presidential Symposium at the 24thEuropean Hematology Association (EHA) Congress
PRESS RELEASES